The impact of phlebotomy in nonalcoholic fatty liver disease: A prospective, randomized, controlled trial

Leon A. Adams, Darrell H. Crawford, Katherine Stuart, Michael J. House, Timothy G. St. Pierre, Malcolm Webb, Helena L.I. Ching, Jenny Kava, Michael Bynevelt, Gerry C. MacQuillan, George Garas, Oyekoya T. Ayonrinde, Trevor A. Mori, Kevin D. Croft, Xianwa Niu, Gary P. Jeffrey, John K. Olynyk – 18 December 2014 – Iron is implicated in the pathogenesis of liver injury and insulin resistance (IR) and thus phlebotomy has been proposed as a treatment for nonalcoholic fatty liver disease (NAFLD).

The impact of phlebotomy in nonalcoholic fatty liver disease: A prospective, randomized, controlled trial

Leon A. Adams, Darrell H. Crawford, Katherine Stuart, Michael J. House, Timothy G. St. Pierre, Malcolm Webb, Helena L.I. Ching, Jenny Kava, Michael Bynevelt, Gerry C. MacQuillan, George Garas, Oyekoya T. Ayonrinde, Trevor A. Mori, Kevin D. Croft, Xianwa Niu, Gary P. Jeffrey, John K. Olynyk – 18 December 2014 – Iron is implicated in the pathogenesis of liver injury and insulin resistance (IR) and thus phlebotomy has been proposed as a treatment for nonalcoholic fatty liver disease (NAFLD).

High liver fibrosis index FIB‐4 is highly predictive of hepatocellular carcinoma in chronic hepatitis B carriers

Beomseok Suh, Sehhoon Park, Dong Wook Shin, Jae Moon Yun, Hyung‐Kook Yang, Su Jong Yu, Cheong‐Il Shin, Jin‐Soo Kim, Eunmi Ahn, Hyejin Lee, Jin Ho Park, BeLong Cho – 12 December 2014 – Screening for hepatocellular carcinoma (HCC) is clinically important given that its early detection has remarkable survival benefits. We investigated the possible role of FIB‐4, a recently developed noninvasive marker for liver fibrosis based on routine laboratory tests, as a clinical indicator for predicting future HCC among hepatitis B surface antigen (HBsAg) carriers.

Activation of the transforming growth factor‐β/SMAD transcriptional pathway underlies a novel tumor‐promoting role of sulfatase 1 in hepatocellular carcinoma

Renumathy Dhanasekaran, Ikuo Nakamura, Chunling Hu, Gang Chen, Abdul M. Oseini, Elif Sezin Seven, Alexander G. Miamen, Catherine D. Moser, Wei Zhou, Toin H. van Kuppevelt, Jan M. van Deursen, Taofic Mounajjed, Martin E. Fernandez‐Zapico, Lewis R. Roberts – 12 December 2014 – In vitro studies have proposed a tumor suppressor role for sulfatase 1 (SULF1) in hepatocellular carcinoma (HCC); however, high expression in human HCC has been associated with poor prognosis. The reason underlying this paradoxical observation remains to be explored.

High liver fibrosis index FIB‐4 is highly predictive of hepatocellular carcinoma in chronic hepatitis B carriers

Beomseok Suh, Sehhoon Park, Dong Wook Shin, Jae Moon Yun, Hyung‐Kook Yang, Su Jong Yu, Cheong‐Il Shin, Jin‐Soo Kim, Eunmi Ahn, Hyejin Lee, Jin Ho Park, BeLong Cho – 12 December 2014 – Screening for hepatocellular carcinoma (HCC) is clinically important given that its early detection has remarkable survival benefits. We investigated the possible role of FIB‐4, a recently developed noninvasive marker for liver fibrosis based on routine laboratory tests, as a clinical indicator for predicting future HCC among hepatitis B surface antigen (HBsAg) carriers.

Vps4A functions as a tumor suppressor by regulating the secretion and uptake of exosomal microRNAs in human hepatoma cells

Jin‐xing Wei, Li‐hong Lv, Yun‐le Wan, Yang Cao, Guo‐lin Li, Hao‐ming Lin, Rui Zhou, Chang‐zhen Shang, Jun Cao, Hai He, Qing‐fang Han, Pei‐qing Liu, Gang Zhou, Jun Min – 12 December 2014 – The deregulation of microRNAs (miRNAs) plays an important role in human hepatocarcinogenesis. In this study, we highlight exosomes as mediators involved in modulating miRNA profiles in hepatocellular carcinoma (HCC) cells. First, we examined the different miRNA expression profiles in HCC cells and HCC cell–derived exosomes.

Subscribe to